Publication | Closed Access

Topoisomerase IIα content and topoisomerase II catalytic activity cannot explain drug sensitivities to topoisomerase II inhibitors in lung cancer cell lines

Tumor BiologyMedicineIi InhibitorsPharmacologyPathologyDrug SensitivitiesCancer BiologyAnti-cancer AgentCancer TreatmentOncologyTopoisomerase Iiα ContentLung CancerCancer Research